Results 71 to 80 of about 56,276 (247)

First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial

Cancer Communications, EarlyView.
Abstract Background The ASTRUM‐005 study previously demonstrated a significant overall survival (OS) benefit with serplulimab (a programmed death 1 inhibitor) plus chemotherapy versus chemotherapy alone in previously untreated extensive‐stage small‐cell lung cancer (ES‐SCLC).
Ying Cheng, Shuang Zhang, Liang Han, Lin Wu, Jun Chen, Peiyan Zhao, Hongmei Sun, Guilan Wen, Yinghua Ji, Anastasia Zimina, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Yuansong Bai, Tamar Melkadze, Yueyin Pan, Xuhong Min, Maksym Viguro, Xingya Li, Yanqiu Zhao, Junquan Yang, Tamta Makharadze, Ekaterine Arkania, Haoyu Yu, Jing Li, Fang Yang, Xinyi Yang, Chen Ling, Qingyu Wang, Yongqiang Shan, Jun Zhu, the ASTRUM‐005 Study Group   +32 more
wiley   +1 more source

Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy

Cancer Communications, EarlyView.
Abstract Background Pancreatic cancer's aberrant lipid metabolism fuels cell growth, invasion, and metastasis, yet its impact on immune surveillance and immunotherapy is unclear. This study investigated how sterol regulatory element‐binding transcription factor 1 (SREBP1)‐driven lipid metabolism affects the tumor microenvironment (TME) in pancreatic ...
Mengyi Lao, Xiaozhen Zhang, Zejun Li, Kang Sun, Hanshen Yang, Sicheng Wang, Lihong He, Yan Chen, Hanjia Zhang, Jiatao Shi, Daqian Xu, Tingbo Liang, Xueli Bai   +12 more
wiley   +1 more source

Humanized Antibodies. Modern Developments and Prospects for the Creation of Medical Protectors Against Biological Threads and Hazards

Вестник войск РХБ защиты
Passive immunization is the variant of the immunization, in which antibodies are introduced into the body in quantities, sufficient to provide a therapeutic effect.
A. S. Gorshkov, D. V. Pechenkin, A. V. Kuznetsovskiy, D. V. Borovskoy   +3 more
doaj   +1 more source

Amyloid‐Related Imaging Abnormality (ARIA) Beyond the APOE‐ε4 Allele

Chronic Diseases and Translational Medicine, EarlyView.
Mechanism of action of monoclonal antibodies targeting Aβ in the treatment of AD. (A) Targets of various mAbs. (B) Mechanism of monoclonal antibody‐mediated clearance of Aβ. mAbs facilitate the clearance of Aβ by enhancing microglial‐mediated phagocytosis through the upregulation of TREM2 expression.
Valentinus Besin, Farizky Martriano Humardani, Fenny Lanawati Yudiarto, Paulus Anam Ong, Sulistyo Emantoko Dwi Putra, Ratih Asmana Ningrum   +5 more
wiley   +1 more source

Pharmacokinetics, Safety, and Tolerability of Single‐Dose Dazukibart in Healthy Adults in China and Japan: Results From 2 Randomized, Double‐Blind, Phase 1 Studies

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Dazukibart is a humanized monoclonal antibody selectively targeting interferon‐β. The pharmacokinetics (PK), safety, tolerability, and immunogenicity of dazukibart were evaluated in 2 double‐blind, randomized, placebo‐controlled, single‐dose, Phase 1 studies in healthy adults in China (Study 1: N = 18; dazukibart 900 mg = 15; placebo = 3) and ...
Naihan Chen, Yamato Sano, Xiaohong Wang, Shuiyi Hu, Junichi Tabira, Xin Luo, Hiroki Yoshimatsu, John Prybylski, Myron Chu, Haiyan Li, Kenji Takazawa   +10 more
wiley   +1 more source

Radiopharmaceuticals in immunoscintigraphy and radioimmunotherapy

Nucleus, 2012
The high morbidity-mortality of cancer makes this condition in Cuba, and at international level, a serious health problem. Radioimmunodiagnosis and radioimmunotherapy based in the growing biotechnological advances, and the actual knowledge of molecular
René Leyva Montaña
doaj  

Safety, Tolerability, and Pharmacokinetics of Donanemab in Healthy Chinese Participants: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Alzheimer's disease (AD), characterized by β‐amyloid (Aβ) plaques and neurofibrillary tangles, is the leading cause of dementia globally. Donanemab is a humanized immunoglobulin G1 in development as a treatment to slow AD progression. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PKs), and immunogenicity of donanemab
Junyu Xu, Nan Zhao, Yihui Wang, Ivelina Gueorguieva, Chenxi Qian, Yimin Cui   +5 more
wiley   +1 more source

Passive immunotherapy for Alzheimer’s disease: challenges & future directions

Journal of Translational Medicine
Passive immunotherapy with specific antibodies targeting Amyloid β (Aβ) peptide or tubulin-associated unit (tau) protein has emerged as a promising therapeutic approach in Alzheimer’s disease (AD).
Ling Xiao Yi, Eng King Tan, Zhi Dong Zhou   +2 more
doaj   +1 more source

Confirmation of Fixed Quarterly Riliprubart Regimen in Patients with Cold Agglutinin Disease Using Population PK/PD and Exposure‐Response Analyses

Clinical Pharmacology &Therapeutics, EarlyView.
Riliprubart is a second‐generation, humanized immunoglobulin G4 that inhibits only the activated form of the C1s component of the proximal classical complement pathway. The clinical studies of riliprubart conducted thus far for the treatment of cold agglutinin disease (CAD), a rare autoimmune disease, include a Phase 1 first‐in‐human study in healthy ...
Timothy Chow, Marek Wardecki, Michael Storek, Nancy Wong   +3 more
wiley   +1 more source

Alemtuzumab Exposure and T Lymphocyte Depletion: A Population Pharmacokinetic‐Pharmacodynamic Model of Alemtuzumab Induction Therapy for Kidney Transplantation

Clinical Pharmacology &Therapeutics, EarlyView.
Alemtuzumab is a T cell‐depleting monoclonal antibody that is used for the prevention of kidney transplant rejection. The duration of lymphodepletion after the current standard induction therapy dose is likely longer than necessary, resulting in prolonged T cell lymphopenia with the associated risk of infections. Here, the interplay between alemtuzumab
Lukas K. van Vugt, Tom C. Zwart, Suzanne Bezstarosti, Sebastiaan Heidt, Marlies E. J. Reinders, Dennis A. Hesselink, Aiko P. J. de Vries, Brenda C. M. de Winter, Dirk Jan A. R. Moes   +8 more
wiley   +1 more source